JAC Advance Access published online on July 10, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm258
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05
1 New Hanover Regional Medical Center, 2131 South 17th Street, Wilmington, NC 28402, USA 2 Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, 280 Calhoun Street, Room QF 219, PO Box 250140, Charleston, SC 29425, USA 3 Cubist Pharmaceuticals, 804 Prince Ferry Lane, Mt. Pleasant, SC 29464, USA
Received 19 April 2007; returned 14 June 2007; accepted 20 June 2007
* Corresponding author. +1-910-343-7078; Fax: +1-901-343-7829; Email: gregory.steinkraus{at}nhhn.org
Objectives: To assess whether methicillin-resistant Staphylococcus aureus (MRSA) vancomycin MIC shifts (MIC creep) at a tertiary care institution occurred that may have gone undetected using traditional susceptibility markers (percentage susceptible, MIC50, MIC90) over a 5 year period. Additionally, MIC trends were evaluated for oxacillin, linezolid and daptomycin.
Methods: Etest MICs were performed on MRSA blood culture isolates (January 2001–December 2005). Only one isolate per patient was studied. The reported Etest MIC result was used and not rounded upward. MIC50, MIC90, median and geometric mean MIC, percentage susceptible and percentage resistant were calculated for each drug in each year. Non-parametric methods (linear correlation and Mantel–Haenszel 
2) were used to assess MIC trends over time and the association of vancomycin, linezolid and daptomycin MICs with oxacillin MICs.
Results: All isolates were susceptible to vancomycin, linezolid and daptomycin and resistant to oxacillin. MICs increased for vancomycin, linezolid and oxacillin (P < 0.0001); however, daptomycin MICs decreased slightly (P = 0.0386). For vancomycin, linezolid and oxacillin, there were significant increases (P < 0.0001) in the percentage of isolates with MICs that were higher than the respective 2001 median MIC, but not for daptomycin (P = 0.1361). Oxacillin MICs were associated with MICs of linezolid (r = 0.364, P < 0.0001), vancomycin (r = 0.353, P < 0.0001) and daptomycin (r = 0.106, P = 0.0063).
Conclusions: Oxacillin, vancomycin and linezolid MICs increased over time. For vancomycin and linezolid, these MIC increases were not reliably detected by percentage susceptibility as they occurred below the susceptibility breakpoint. Although the MICs of all agents appeared to be associated with increasing oxacillin MICs, the strongest associations were noted for vancomycin and linezolid.
Key Words: daptomycin , linezolid , susceptibility
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Patel, P. Lubanski, S. Ferro, M. Bonafede, S. Harrington, A. Evans, K. Stellrecht, and T. P. Lodise Correlation between Vancomycin MIC Values and Those of Other Agents against Gram-Positive Bacteria among Patients with Bloodstream Infections Caused by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5141 - 5144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Shields, J. L. Martello, B. A. Potoski, G. Sakoulas, and P. A. Moise Is Vancomycin Ototoxicity a Significant Risk? Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4572 - 4573. [Full Text] [PDF]
|
|
|
|
|
|
S. Svetitsky, L. Leibovici, and M. Paul Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4069 - 4079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Sader, P. D. Fey, D. N. Fish, A. P. Limaye, G. Pankey, J. Rahal, M. J. Rybak, D. R. Snydman, L. L. Steed, K. Waites, et al. Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006 Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4127 - 4132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Sader, P. R. Rhomberg, and R. N. Jones Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., July 1, 2009; 53(7): 3162 - 3165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Krievins, R. Brandt, S. Hawser, P. Hadvary, and K. Islam Multicenter, Randomized Study of the Efficacy and Safety of Intravenous Iclaprim in Complicated Skin and Skin Structure Infections Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2834 - 2840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Legendre Is vancomycin obsolete? Am. J. Health Syst. Pharm., June 1, 2009; 66(11): 977 - 978. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Musta, K. Riederer, S. Shemes, P. Chase, J. Jose, L. B. Johnson, and R. Khatib Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years J. Clin. Microbiol., June 1, 2009; 47(6): 1640 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Mason, L. B. Lamberth, W. A. Hammerman, K. G. Hulten, J. Versalovic, and S. L. Kaplan Vancomycin MICs for Staphylococcus aureus Vary by Detection Method and Have Subtly Increased in a Pediatric Population Since 2005 J. Clin. Microbiol., June 1, 2009; 47(6): 1628 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Moise, D. S. Smyth, D. A. Robinson, N. El-Fawal, C. McCalla, and G. Sakoulas Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies J. Antimicrob. Chemother., May 1, 2009; 63(5): 873 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pea, M. Furlanut, C. Negri, F. Pavan, M. Crapis, F. Cristini, and P. Viale Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1863 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Sader, T. R. Fritsche, and R. N. Jones Potency and Bactericidal Activity of Iclaprim against Recent Clinical Gram-Positive Isolates Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2171 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Forouzesh, P. A. Moise, and G. Sakoulas Vancomycin Ototoxicity: a Reevaluation in an Era of Increasing Doses Antimicrob. Agents Chemother., February 1, 2009; 53(2): 483 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rybak, B. Lomaestro, J. C. Rotschafer, R. Moellering Jr., W. Craig, M. Billeter, J. R. Dalovisio, and D. P. Levine Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am. J. Health Syst. Pharm., January 1, 2009; 66(1): 82 - 98. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Levine Clinical experience with daptomycin: bacteraemia and endocarditis J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii35 - iii39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Future directions with daptomycin J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii41 - iii49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-I. Alos, A. Garcia-Canas, P. Garcia-Hierro, and F. Rodriguez-Salvanes Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage J. Antimicrob. Chemother., October 1, 2008; 62(4): 773 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Lodise, J. Graves, A. Evans, E. Graffunder, M. Helmecke, B. M. Lomaestro, and K. Stellrecht Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3315 - 3320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Rybak, S. N. Leonard, K. L. Rossi, C. M. Cheung, H. S. Sadar, and R. N. Jones Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007) J. Clin. Microbiol., September 1, 2008; 46(9): 2950 - 2954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Marco, C. Garcia de la Maria, Y. Armero, E. Amat, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, et al. Daptomycin Is Effective in Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2538 - 2543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chua, C. L. Moore, M. B. Perri, S. M. Donabedian, W. Masch, D. Vager, S. L. Davis, K. Lulek, B. Zimnicki, and M. J. Zervos Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates in Urban Detroit J. Clin. Microbiol., July 1, 2008; 46(7): 2345 - 2352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A Moise, R. S Castro, C. Sul, A. Forrest, and G. Sakoulas Relationship of Linezolid Minimum Inhibitory Concentration and Time to Bacterial Eradication in Treatment for Methicillin-Resistant Staphylococcus aureus Infection Ann. Pharmacother., April 1, 2008; 42(4): 592 - 593. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Holmes and J. H. Jorgensen Inhibitory Activities of 11 Antimicrobial Agents and Bactericidal Activities of Vancomycin and Daptomycin against Invasive Methicillin-Resistant Staphylococcus aureus Isolates Obtained from 1999 through 2006 Antimicrob. Agents Chemother., February 1, 2008; 52(2): 757 - 760. [Abstract] [Full Text] [PDF]
|
|